1
|
Sudduth ER, Trautmann-Rodriguez M, Gill N, Bomb K, Fromen CA. Aerosol pulmonary immune engineering. Adv Drug Deliv Rev 2023; 199:114831. [PMID: 37100206 PMCID: PMC10527166 DOI: 10.1016/j.addr.2023.114831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Revised: 03/23/2023] [Accepted: 04/14/2023] [Indexed: 04/28/2023]
Abstract
Aerosolization of immunotherapies poses incredible potential for manipulating the local mucosal-specific microenvironment, engaging specialized pulmonary cellular defenders, and accessing mucosal associated lymphoid tissue to redirect systemic adaptive and memory responses. In this review, we breakdown key inhalable immunoengineering strategies for chronic, genetic, and infection-based inflammatory pulmonary disorders, encompassing the historic use of immunomodulatory agents, the transition to biological inspired or derived treatments, and novel approaches of complexing these materials into drug delivery vehicles for enhanced release outcomes. Alongside a brief description of key immune targets, fundamentals of aerosol drug delivery, and preclinical pulmonary models for immune response, we survey recent advances of inhaled immunotherapy platforms, ranging from small molecules and biologics to particulates and cell therapies, as well as prophylactic vaccines. In each section, we address the formulation design constraints for aerosol delivery as well as advantages for each platform in driving desirable immune modifications. Finally, prospects of clinical translation and outlook for inhaled immune engineering are discussed.
Collapse
Affiliation(s)
- Emma R Sudduth
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA
| | | | - Nicole Gill
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA
| | - Kartik Bomb
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA
| | - Catherine A Fromen
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA.
| |
Collapse
|
2
|
Kunde SS, Ghosh R, Wairkar S. Emerging trends in pulmonary delivery of biopharmaceuticals. Drug Discov Today 2022; 27:1474-1482. [PMID: 35143963 DOI: 10.1016/j.drudis.2022.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Revised: 08/21/2021] [Accepted: 02/03/2022] [Indexed: 11/03/2022]
Abstract
Over the years, a tendency toward biopharmaceutical products as therapeutics has been witnessed compared with small molecular drugs. Biopharmaceuticals possess greater specificity, selectivity and potency with fewer side effects. The pulmonary route is a potential noninvasive route studied for the delivery of various molecules, including biopharmaceuticals. It directly delivers drugs to the lungs in higher concentrations and provides greater bioavailability than other noninvasive routes. This review focuses on the pulmonary route for the delivery of biopharmaceuticals. We have covered various biopharmaceuticals, including peptides, recombinant proteins, enzymes, monoclonal antibodies and nucleic acids, administered via a pulmonary route and discussed their rewards and drawbacks.
Collapse
Affiliation(s)
- Shalvi Sinai Kunde
- Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKMs NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai, Maharashtra 400056, India
| | - Ritushree Ghosh
- Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKMs NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai, Maharashtra 400056, India
| | - Sarika Wairkar
- Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKMs NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai, Maharashtra 400056, India.
| |
Collapse
|
3
|
Protein and peptide delivery to lungs by using advanced targeted drug delivery. Chem Biol Interact 2021; 351:109706. [PMID: 34662570 DOI: 10.1016/j.cbi.2021.109706] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2021] [Revised: 09/16/2021] [Accepted: 10/13/2021] [Indexed: 11/20/2022]
Abstract
The challenges and difficulties associated with conventional drug delivery systems have led to the emergence of novel, advanced targeted drug delivery systems. Therapeutic drug delivery of proteins and peptides to the lungs is complicated owing to the large size and polar characteristics of the latter. Nevertheless, the pulmonary route has attracted great interest today among formulation scientists, as it has evolved into one of the important targeted drug delivery platforms for the delivery of peptides, and related compounds effectively to the lungs, primarily for the management and treatment of chronic lung diseases. In this review, we have discussed and summarized the current scenario and recent developments in targeted delivery of proteins and peptide-based drugs to the lungs. Moreover, we have also highlighted the advantages of pulmonary drug delivery over conventional drug delivery approaches for peptide-based drugs, in terms of efficacy, retention time and other important pharmacokinetic parameters. The review also highlights the future perspectives and the impact of targeted drug delivery on peptide-based drugs in the coming decade.
Collapse
|
4
|
Microneedle Mediated Transdermal Delivery of Protein, Peptide and Antibody Based Therapeutics: Current Status and Future Considerations. Pharm Res 2020; 37:117. [PMID: 32488611 PMCID: PMC7266419 DOI: 10.1007/s11095-020-02844-6] [Citation(s) in RCA: 47] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2020] [Accepted: 05/21/2020] [Indexed: 02/08/2023]
Abstract
The success of protein, peptide and antibody based therapies is evident - the biopharmaceuticals market is predicted to reach $388 billion by 2024 [1], and more than half of the current top 20 blockbuster drugs are biopharmaceuticals. However, the intrinsic properties of biopharmaceuticals has restricted the routes available for successful drug delivery. While providing 100% bioavailability, the intravenous route is often associated with pain and needle phobia from a patient perspective, which may translate as a reluctance to receive necessary treatment. Several non-invasive strategies have since emerged to overcome these limitations. One such strategy involves the use of microneedles (MNs), which are able to painlessly penetrate the stratum corneum barrier to dramatically increase transdermal drug delivery of numerous drugs. This review reports the wealth of studies that aim to enhance transdermal delivery of biopharmaceutics using MNs. The true potential of MNs as a drug delivery device for biopharmaceuticals will not only rely on acceptance from prescribers, patients and the regulatory authorities, but the ability to upscale MN manufacture in a cost-effective manner and the long term safety of MN application. Thus, the current barriers to clinical translation of MNs, and how these barriers may be overcome are also discussed.
Collapse
|
5
|
Bai L, Fei Q, Lei F, Luo R, Ma Q, Dai M, Zhang H, He N. Comparative analysis of pharmacokinetics of vancomycin hydrochloride in rabbits after ocular, intragastric, and intravenous administration by LC-MS/MS. Xenobiotica 2020; 50:1461-1468. [PMID: 32452710 DOI: 10.1080/00498254.2020.1774681] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
The objective of this study was to compare the pharmacokinetics of vancomycin hydrochloride administered into rabbits through different routes and explore the feasibility of peptide drugs entering the systemic circulation through ocular administration. A convenient, accurate, and rapid liquid chromatography-trandem mass spectrometric (LC-MS/MS) method was established and used for the determination of vancomycin hydrochloride in rabbit plasma after intravenous administration (1.5 mg/kg), intragastric, and ocular administration (15 mg/kg). The pharmacokinetic parameters were analyzed using the DAS 2.0 software. We obtained a linear calibration curves vancomycin hydrochloride in plasma of rabbits over a concentration range of 0.05-10.0 μg/mL (R 2 > 0.9995), the interassay accuracy was within 5%, precision of 1.66-3.38%, and recovery of >85%. No matrix effects were observed. The absolute bioavailability of vancomycin hydrochloride after intragastric and ocular administration was 1.0 and 7.3%, with the half-life values of 63.1 and 138.5 min, respectively. Therefore, the LC-MS/MS method established in this experiment was suitable for the determination of vancomycin hydrochloride. Vancomycin hydrochloride was rapidly absorbed into the blood circulation after ocular administration. Ocular administration was linked to higher bioavailability compared with intragastric administration, suggesting that the former will become a route for the delivery of peptide drugs.
Collapse
Affiliation(s)
- Luyu Bai
- Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
| | - Qingsong Fei
- Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
| | - Fang Lei
- Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
| | - Rui Luo
- Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
| | - Qun Ma
- Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
| | - Manman Dai
- Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
| | - Huimin Zhang
- Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
| | - Ning He
- Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.,Anhui Academy of Chinese Medical Sciences, Institute of Pharmaceutics, Hefei, China.,Engineering Technology Research Center of Modernized Pharmaceutics, Hefei, China.,Key Laboratory of Chinese Medicinal Formula, Hefei, China
| |
Collapse
|
6
|
Tsao C, Yuan Z, Zhang P, Liu E, McMullen P, Wu K, Hung HC, Jiang S. Enhanced pulmonary systemic delivery of protein drugs via zwitterionic polymer conjugation. J Control Release 2020; 322:170-176. [PMID: 32200000 DOI: 10.1016/j.jconrel.2020.03.019] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Revised: 02/27/2020] [Accepted: 03/15/2020] [Indexed: 01/09/2023]
Abstract
Pulmonary delivery of protein drugs into the systemic circulation is highly desirable as the lung provides a large absorption surface area and a more favorable environment for biologics compared to other delivery routes. However, pulmonary systemic delivery of proteins presents several challenges such as poor protein stability and limited bioavailability, especially for large proteins (molecular weight > 50 kDa), which exhibit an average bioavailability of 1% to 5% when delivered via the pulmonary route. Here, we demonstrated that with the conjugation of zwitterionic poly(carboxybetaine) (pCB) polymer, the bioavailability of organophosphate hydrolase (OPH) was significantly increased from 5% to 53%. OPH conjugated with pCB delivered through intubation-assisted intratracheal instillation (IAIS) into the lung exhibited improved pharmacokinetic properties and prophylactic efficacy against organophosphate poisoning, showing its application potential. Zwitterionic polymer conjugation provides the possibility for a favorable, non-invasive delivery of biological therapeutics into the systemic circulation.
Collapse
Affiliation(s)
- Caroline Tsao
- Department of Chemical Engineering, University of Washington, Seattle, WA 98195, United States of America
| | - Zhefan Yuan
- Department of Chemical Engineering, University of Washington, Seattle, WA 98195, United States of America
| | - Peng Zhang
- Department of Chemical Engineering, University of Washington, Seattle, WA 98195, United States of America
| | - Erik Liu
- Department of Chemical Engineering, University of Washington, Seattle, WA 98195, United States of America
| | - Patrick McMullen
- Department of Chemical Engineering, University of Washington, Seattle, WA 98195, United States of America
| | - Kan Wu
- Department of Chemical Engineering, University of Washington, Seattle, WA 98195, United States of America
| | - Hsiang-Chieh Hung
- Department of Chemical Engineering, University of Washington, Seattle, WA 98195, United States of America
| | - Shaoyi Jiang
- Department of Chemical Engineering, University of Washington, Seattle, WA 98195, United States of America.
| |
Collapse
|
7
|
Alp G, Aydogan N. Lipid-based mucus penetrating nanoparticles and their biophysical interactions with pulmonary mucus layer. Eur J Pharm Biopharm 2020; 149:45-57. [PMID: 32014491 DOI: 10.1016/j.ejpb.2020.01.017] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2019] [Revised: 10/25/2019] [Accepted: 01/29/2020] [Indexed: 12/27/2022]
Abstract
Lungs are critical organs that are continuously exposed to exogeneous matter. The presence of the mucus layer helps to protect them via its adhesive structure and filtering mechanisms. Mucus also acts as a strong barrier against the drugs and nanocarriers in drug delivery. In this study, solid lipid nanoparticles (SLNs), at different sizes and surface properties, were prepared and their spreading/penetration ability was tested for their use in pulmonary drug delivery. The biophysical interactions of SLNs have been studied via light scattering (LS) and zeta potential analyses by incubating the SLNs in mucin solution and forming a model mucus layer using a Langmuir-Blodgett (LB) trough. In addition, the penetration performance of the particles was evaluated using Franz diffusion cell and rotating diffusion tubes. It was determined that 36% of SLNs can penetrate through a 1.2 ± 0.2-mm-thick mucus layer. Finally, the spreading behavior of the particles on a mucus-mimicking subphase was characterized and enhanced using a catanionic surfactant mixture. Overall, the current study was the first to investigates both the spreading and penetration performance of SLNs. The developed systems offer a drug delivery system that is able to achieve high penetration rates through a thick mucus layer.
Collapse
Affiliation(s)
- Gokce Alp
- Department of Chemical Engineering, Hacettepe University, Beytepe 06800, Ankara, Turkey
| | - Nihal Aydogan
- Department of Chemical Engineering, Hacettepe University, Beytepe 06800, Ankara, Turkey.
| |
Collapse
|
8
|
Brunaugh AD, Wu T, Kanapuram SR, Smyth HDC. Effect of Particle Formation Process on Characteristics and Aerosol Performance of Respirable Protein Powders. Mol Pharm 2019; 16:4165-4180. [PMID: 31448924 DOI: 10.1021/acs.molpharmaceut.9b00496] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Pulmonary delivery of biopharmaceuticals may enable targeted local therapeutic effect and noninvasive systemic administration. Dry powder inhaler (DPI) delivery is an established patient-friendly approach for delivering large molecules to the lungs; however, the complexities of balancing protein stability with aerosol performance require that the design space of biopharmaceutical DPI formulations is rigorously explored. Utilizing four rationally selected formulations obtained using identical atomization conditions, an extensive study of the effect of the particle formation process (spray drying or spray freeze-drying) on powder properties, aerosol performance, and protein stability was performed. Multiple linear regression analysis was used to understand the relationship between powder properties, device dispersion mechanism, and aerosol performance. Spray drying and spray freeze-drying, despite the same spraying conditions, produced powders with vastly different physical characteristics, though similar aerosol performance. The resulting regression model points to the significance of particle size, density, and surface properties on the resulting aerosol performance, with these factors weighing differently according to the device dispersion mechanism utilized (shear-based or impaction-based). The physical properties of the produced spray dried and spray freeze-dried powders have differing implications for long-term stability, which will be explored extensively in a future study.
Collapse
Affiliation(s)
- Ashlee D Brunaugh
- College of Pharmacy , The University of Texas at Austin , 2409 West University Avenue, PHR 4.214 , Austin , Texas 78712 , United States
| | - Tian Wu
- Amgen , One Amgen Center Drive , Thousand Oaks , California 91320 , United States
| | - Sekhar R Kanapuram
- Amgen , One Amgen Center Drive , Thousand Oaks , California 91320 , United States
| | - Hugh D C Smyth
- College of Pharmacy , The University of Texas at Austin , 2409 West University Avenue, PHR 4.214 , Austin , Texas 78712 , United States
| |
Collapse
|
9
|
Abstract
Most clinically approved drugs (primarily small molecules or antibodies) are rapidly cleared from circulation and distribute throughout the body. As a consequence, only a small portion of the dose accumulates at the target site, leading to low efficacy and adverse side effects. Therefore, new delivery strategies are necessary to increase organ and tissue-specific delivery of therapeutic agents. Nanoparticles provide a promising approach for prolonging the circulation time and improving the biodistribution of drugs. However, nanoparticles display several limitations, such as clearance by the immune systems and impaired diffusion in the tissue microenvironment. To overcome common nanoparticle limitations various functionalization and targeting strategies have been proposed. This review will discuss synthetic nanoparticle and extracellular vesicle delivery strategies that exploit organ-specific features to enhance drug accumulation at the target site.
Collapse
|
10
|
Wilson EM, Luft JC, DeSimone JM. Formulation of High-Performance Dry Powder Aerosols for Pulmonary Protein Delivery. Pharm Res 2018; 35:195. [PMID: 30141117 DOI: 10.1007/s11095-018-2452-z] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Accepted: 06/20/2018] [Indexed: 10/28/2022]
Abstract
PURPOSE Pulmonary delivery of biologics is of great interest, as it can be used for the local treatment of respiratory diseases or as a route to systemic drug delivery. To reach the full potential of inhaled biologics, a formulation platform capable of producing high performance aerosols without altering protein native structure is required. METHODS A formulation strategy using Particle Replication in Non-wetting Templates (PRINT) was developed to produce protein dry powders with precisely engineered particle morphology. Stability of the incorporated proteins was characterized and the aerosol properties of the protein dry powders was evaluated in vitro with an Andersen Cascade Impactor (ACI). RESULTS Model proteins bovine serum albumin (BSA) and lysozyme were micromolded into 1 μm cylinders composed of more than 80% protein, by mass. Extensive characterization of the incorporated proteins found no evidence of alteration of native structures. The BSA formulation produced a mass median aerodynamic diameter (MMAD) of 1.77 μm ± 0.06 and a geometric standard deviation (GSD) of 1.51 ± 0.06 while the lysozyme formulation had an MMAD of 1.83 μm ± 0.12 and a GSD of 1.44 ± 0.03. CONCLUSION Protein dry powders manufactured with PRINT could enable high-performance delivery of protein therapeutics to the lungs.
Collapse
Affiliation(s)
- Erin M Wilson
- Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy, University of North Carolina at Chapel Hill,, Chapel Hill, North Carolina, USA
| | - J Christopher Luft
- Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy, University of North Carolina at Chapel Hill,, Chapel Hill, North Carolina, USA
| | - Joseph M DeSimone
- Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy, University of North Carolina at Chapel Hill,, Chapel Hill, North Carolina, USA. .,Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. .,Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill,, Chapel Hill, North Carolina, USA. .,Department of Chemical and Biomolecular Engineering, North Carolina State University,, Raleigh, North Carolina, USA.
| |
Collapse
|
11
|
Pope CN, Brimijoin S. Cholinesterases and the fine line between poison and remedy. Biochem Pharmacol 2018; 153:205-216. [PMID: 29409903 PMCID: PMC5959757 DOI: 10.1016/j.bcp.2018.01.044] [Citation(s) in RCA: 74] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2017] [Accepted: 01/26/2018] [Indexed: 12/20/2022]
Abstract
Acetylcholinesterase (AChE, EC 3.1.1.7) and butyrylcholinesterase (BChE, EC 3.1.1.8) are related enzymes found across the animal kingdom. The critical role of acetylcholinesterase in neurotransmission has been known for almost a century, but a physiological role for butyrylcholinesterase is just now emerging. The cholinesterases have been deliberately targeted for both therapy and toxicity, with cholinesterase inhibitors being used in the clinic for a variety of disorders and conversely for their toxic potential as pesticides and chemical weapons. Non-catalytic functions of the cholinesterases (ChEs) participate in both neurodevelopment and disease. Manipulating either the catalytic activities or the structure of these enzymes can potentially shift the balance between beneficial and adverse effect in a wide number of physiological processes.
Collapse
Affiliation(s)
- Carey N Pope
- Department of Physiological Sciences, Interdisciplinary Toxicology Program, Oklahoma State University, Stillwater, OK 74078, USA.
| | - Stephen Brimijoin
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55902, USA
| |
Collapse
|
12
|
Alp G, Aydogan N. Enhancing the Spreading Behavior on Pulmonary Mucus Mimicking Subphase via Catanionic Surfactant Solutions: Toward Effective Drug Delivery through the Lungs. Mol Pharm 2018; 15:1361-1370. [DOI: 10.1021/acs.molpharmaceut.8b00086] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
13
|
Chen R, Xu L, Fan Q, Li M, Wang J, Wu L, Li W, Duan J, Chen Z. Hierarchical pulmonary target nanoparticles via inhaled administration for anticancer drug delivery. Drug Deliv 2017; 24:1191-1203. [PMID: 28844172 PMCID: PMC8241141 DOI: 10.1080/10717544.2017.1365395] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Inhalation administration, compared with intravenous administration, significantly enhances chemotherapeutic drug exposure to the lung tissue and may increase the therapeutic effect for pulmonary anticancer. However, further identification of cancer cells after lung deposition of inhaled drugs is necessary to avoid side effects on normal lung tissue and to maximize drug efficacy. Moreover, as the action site of the major drug was intracellular organelles, drug target to the specific organelle is the final key for accurate drug delivery. Here, we designed a novel multifunctional nanoparticles (MNPs) for pulmonary antitumor and the material was well-designed for hierarchical target involved lung tissue target, cancer cell target, and mitochondrial target. The biodistribution in vivo determined by UHPLC–MS/MS method was employed to verify the drug concentration overwhelmingly increasing in lung tissue through inhaled administration compared with intravenous administration. Cellular uptake assay using A549 cells proved the efficient receptor-mediated cell endocytosis. Confocal laser scanning microscopy observation showed the location of MNPs in cells was mitochondria. All results confirmed the intelligent material can progressively play hierarchical target functions, which could induce more cell apoptosis related to mitochondrial damage. It provides a smart and efficient nanocarrier platform for hierarchical targeting of pulmonary anticancer drug. So far, this kind of material for pulmonary mitochondrial-target has not been seen in other reports.
Collapse
Affiliation(s)
- Rui Chen
- a College of Pharmacy , Nanjing University of Chinese Medicine , Nanjing , China
| | - Liu Xu
- a College of Pharmacy , Nanjing University of Chinese Medicine , Nanjing , China
| | - Qin Fan
- a College of Pharmacy , Nanjing University of Chinese Medicine , Nanjing , China
| | - Man Li
- a College of Pharmacy , Nanjing University of Chinese Medicine , Nanjing , China
| | - Jingjing Wang
- a College of Pharmacy , Nanjing University of Chinese Medicine , Nanjing , China
| | - Li Wu
- a College of Pharmacy , Nanjing University of Chinese Medicine , Nanjing , China
| | - Weidong Li
- a College of Pharmacy , Nanjing University of Chinese Medicine , Nanjing , China
| | - Jinao Duan
- a College of Pharmacy , Nanjing University of Chinese Medicine , Nanjing , China.,b Collaborative Innovation Center of Chinese Medicinal Resources Industrialization , Nanjing , China
| | - Zhipeng Chen
- a College of Pharmacy , Nanjing University of Chinese Medicine , Nanjing , China.,b Collaborative Innovation Center of Chinese Medicinal Resources Industrialization , Nanjing , China
| |
Collapse
|